modafinil has been researched along with HIV in 3 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Excerpt | Relevance | Reference |
---|---|---|
"To evaluate the efficacy and safety of modafinil in the treatment of fatigue in patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and to assess effect on depressive symptoms." | 9.14 | Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. ( McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2010) |
"This pilot study shows encouraging results for modafinil in alleviation of fatigue in HIV+ patients." | 9.11 | Modafinil treatment for fatigue in HIV+ patients: a pilot study. ( Ferrando, SJ; McElhiney, MC; Rabkin, JG; Rabkin, R, 2004) |
"To evaluate the efficacy and safety of modafinil in the treatment of fatigue in patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and to assess effect on depressive symptoms." | 5.14 | Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. ( McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2010) |
"This pilot study shows encouraging results for modafinil in alleviation of fatigue in HIV+ patients." | 5.11 | Modafinil treatment for fatigue in HIV+ patients: a pilot study. ( Ferrando, SJ; McElhiney, MC; Rabkin, JG; Rabkin, R, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
McElhiney, M | 1 |
Rabkin, J | 1 |
Van Gorp, W | 1 |
Rabkin, R | 3 |
Rabkin, JG | 2 |
McElhiney, MC | 2 |
McGrath, PJ | 1 |
Ferrando, SJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS[NCT01158443] | Phase 4 | 46 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
Modafinil Treatment for Fatigue in HIV+ Patients[NCT00118378] | Phase 4 | 115 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
Armodafinil Treatment for Fatigue in HIV+ Patients[NCT00737204] | Phase 4 | 70 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
CD4 cell count is a laboratory marker providing an indication of immune functioning. Blood was drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of >= 100 cells. A higher number is associated with better immune functioning. (NCT00118378)
Timeframe: Measured at baseline and Week 4
Intervention | Cells/mcL (Mean) | |
---|---|---|
Baseline CD4 cell count | Week 4 CD4 cell count | |
Modafinil | 481 | 466 |
Placebo | 459 | 482 |
The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9 to 63, with a higher value indicating greater impairment due to fatigue. (NCT00118378)
Timeframe: Measured at baseline and Week 4
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline FSS | Week 4 FSS | |
Modafinil | 52 | 34 |
Placebo | 52 | 43 |
"HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50-100,000 copies), this measure is presented in log10. We entered the log10 value of 1.69 when the laboratory result stated under 50 copies, which was the assay's lowest limit of detectability during the study." (NCT00118378)
Timeframe: Measured at baseline and Week 4
Intervention | Log10 copies/mL (Mean) | |
---|---|---|
Baseline Log10 Viral Load | Week 4 Log10 Viral load | |
Modafinil | 2.53 | 2.31 |
Placebo | 2.41 | 2.30 |
The Role Function Scale includes 10 items drawn from the Short Form 36-item Health Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10 to 50. (NCT00118378)
Timeframe: Measured at baseline and Week 4
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline Role Function Scale | Week 4 Role Function Scale | |
Modafinil | 39 | 22 |
Placebo | 36 | 27 |
Cd4 cell count is a laboratory marker providing an indication of immune system functioning. Blood samples were drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of >=100 cells. A higher number is associated with better immune functioning. (NCT00737204)
Timeframe: Measured at baseline and Week 4
Intervention | Cells/mcL (Mean) | |
---|---|---|
Baseline CD4 cell count | Week 4 CD4 cell count | |
Armodafinil | 502 | 503 |
Placebo | 450 | 445 |
The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9-63, with a higher score indicating greater impairment due to fatigue. (NCT00737204)
Timeframe: Measured at baseline and Weeks 4
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline FSS | Week 4 FSS | |
Armodafinil | 52.6 | 25.8 |
Placebo | 53.1 | 39.4 |
"HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50 - 100,000 copies), this measure is transformed to log10 values. We entered the log10 value of 1.69 when the laboratory result stated under 50 copies, which was the assay's lowest limit of detectability during the study." (NCT00737204)
Timeframe: Measured at baseline and Week 4
Intervention | Log10 copies/mL (Mean) | |
---|---|---|
Baseline Log10 Viral Load | Week 4 Log10 Viral load | |
Armodafinil | 2.17 | 2.15 |
Placebo | 2.39 | 2.24 |
The Role Function Scale includes 10 items drawn from the Short Form 36-item Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10-50. (NCT00737204)
Timeframe: Measured at Baseline and Week 4
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline Role Function Scale | Week 4 Role Function Scale | |
Armodafinil | 36.2 | 19.9 |
Placebo | 37.8 | 28.3 |
3 trials available for modafinil and HIV
Article | Year |
---|---|
Effect of armodafinil on cognition in patients with HIV/AIDS and fatigue.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Benzhydryl Compounds; CD4 Lymphocyte Count; Central | 2013 |
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L | 2010 |
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L | 2010 |
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L | 2010 |
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L | 2010 |
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys | 2004 |
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys | 2004 |
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys | 2004 |
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys | 2004 |